Related Experiment Videos
Does vancomycine increase aminoglycoside nephrotoxicity?
A Törel Ergür1, B Onarlioglu, Y Günay
1Department of Pediatrics, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
Abstract:
Vancomycine and amikacin combined is an effective antibiotic combination used in the treatment of serious Gram-positive bacteremia in childhood. However, both drugs may have a potential nephrotoxic effect when used individually. The present study investigates whether the nephrotoxicity of these drugs that display a nephrotoxic effect when used separately increases when used in a combined manner. Ten 2-month-old rats were subjected to intraperitoneal injections of vancomycine (100 mg/kg) and amikacin (80 mg/kg) and ten other 2-month-old rats were administered amikacin (80 mg/kg) for a period of 15 days. The control group of animals consisting of five 2-month old rats were untreated. The renal tissues obtained by laparotomy were processed for both light and electron microscopy. Paraffin sections and ultrathin sections were evaluated in order to determine the renal structure of the control and the experimental groups. In addition, serum creatinine and blood, urea and nitrogen (BUN) levels were measured in blood samples obtained from the rats. In the amikacin and combined amikacin-vancomycine treatment groups, renal morphological changes were observed at the glomerular and tubular levels when compared to the control group, and the serum creatinine and BUN levels were also higher in these groups. Although both experimental groups were different from the control group, they had similar morphological and biochemical features. It was concluded that vancomycine did not influence the nephrotoxic effect of amikacin and both drugs could be used in a combined manner.
Insights
Vancomycin and amikacin combination therapy for serious infections did not increase kidney damage in rats. This study suggests the combined use of these antibiotics is safe regarding nephrotoxicity.
Area of Science:
- Pharmacology
- Nephrology
- Toxicology
Background:
- Vancomycin and amikacin are crucial for treating Gram-positive bacteremia.
- Both antibiotics possess individual nephrotoxic potential.
- The combined nephrotoxicity of vancomycin and amikacin requires investigation.
Purpose of the Study:
- To evaluate if combined vancomycin and amikacin administration exacerbates nephrotoxicity compared to individual use.
- To assess the impact of combined antibiotic therapy on renal structure and function.
Main Methods:
- A 15-day study involving three groups of rats: combined vancomycin-amikacin, amikacin alone, and a control group.
- Renal tissues examined using light and electron microscopy.
- Serum creatinine and blood urea nitrogen (BUN) levels measured.
Main Results:
- Both amikacin and combined vancomycin-amikacin groups showed glomerular and tubular renal morphological changes.
- Elevated serum creatinine and BUN levels were observed in both treatment groups compared to controls.
- No significant difference in nephrotoxicity was found between the individual amikacin and combined therapy groups.
Conclusions:
- Vancomycin does not appear to potentiate the nephrotoxic effects of amikacin.
- Combined vancomycin and amikacin therapy can be considered safe for use in pediatric bacteremia treatment regarding kidney function.